Disease progression model of 4T1 metastatic breast cancer.


Journal

Journal of pharmacokinetics and pharmacodynamics
ISSN: 1573-8744
Titre abrégé: J Pharmacokinet Pharmacodyn
Pays: United States
ID NLM: 101096520

Informations de publication

Date de publication:
02 2020
Historique:
received: 16 07 2019
accepted: 09 01 2020
pubmed: 24 1 2020
medline: 4 5 2021
entrez: 24 1 2020
Statut: ppublish

Résumé

Cancer metastasis is the main cause of death in various types of cancer. However, in the field of pharmacometrics, cancer disease progression models focus on the growth of primary tumors with tumor volume or weight as target values, while the metastasis process is less mentioned. We propose a series of mathematical models to quantitatively describe and predict the disease progression of 4T1 breast cancer in the aspect of primary breast tumor, lung metastasis and white blood cell. The 4T1 cells were injected into breast fat pad of female BALB/c mice to establish an animal model of breast cancer metastasis. The number and volume of lung metastases at different times were measured. Based on the above data, a disease progression model of breast cancer lung metastasis was established and parameter values were estimated. The white blood cell growth and the primary tumor growth of 4T1 mouse are also modeled. The established models can describe the lung metastasis of 4T1 breast cancer in three aspects: (1) the increase in metastasis number; (2) the growth of metastasis volume; (3) metastasis number-size distribution at different time points. Compared with the prior metastasis models based on von Forester equation, our models distinguished the growth rate of primary tumor and metastasis and got parameter values for 4T1 mouse model. And the current models optimized the metastasis number-size distribution model by utilizing logistic function instead of the prior power function. This study provides a comprehensive description of lung metastasis progression for 4T1 breast cancer model, as well as an alternative disease progression model structure for further pharmacodynamics modeling.

Identifiants

pubmed: 31970615
doi: 10.1007/s10928-020-09673-5
pii: 10.1007/s10928-020-09673-5
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

105-116

Subventions

Organisme : Natural Science Foundation of Beijing Municipality (CN)
ID : 7192100
Pays : International

Références

Math Biosci. 2002 Jul-Aug;179(1):21-55
pubmed: 12047920
Cancer Res. 2008 May 15;68(10):3645-54
pubmed: 18483246
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21248-55
pubmed: 21081700
Int J Urol. 2001 Sep;8(9):473-7
pubmed: 11683965
PLoS Comput Biol. 2015 Nov 23;11(11):e1004626
pubmed: 26599078
Cancer Res. 2009 Oct 1;69(19):7529-37
pubmed: 19773447
BMC Cancer. 2012 Mar 27;12:120
pubmed: 22452810
Nat Rev Cancer. 2009 Apr;9(4):285-93
pubmed: 19308068
J Control Release. 2011 May 30;152(1):84-9
pubmed: 21295088
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
Clin Cancer Res. 2016 Aug 1;22(15):3725-33
pubmed: 27252414
J Exp Med. 2001 Mar 19;193(6):727-40
pubmed: 11257139
Cancer Res. 1988 Dec 15;48(24 Pt 1):7067-71
pubmed: 3191483
Tumour Biol. 2013 Aug;34(4):2019-30
pubmed: 23686802
J Pharmacokinet Pharmacodyn. 2016 Dec;43(6):549-565
pubmed: 27771815
Nat Rev Cancer. 2003 Jun;3(6):453-8
pubmed: 12778135
Medicine (Baltimore). 2016 Jun;95(25):e3865
pubmed: 27336872
Cancer Res. 2004 Feb 1;64(3):1094-101
pubmed: 14871843
Cancer Cell. 2016 Nov 14;30(5):668-681
pubmed: 27846389
Clin Pharmacokinet. 2016 Oct;55(10):1251-1269
pubmed: 27154065
Nature. 2005 Dec 8;438(7069):820-7
pubmed: 16341007
Elife. 2015 Jun 18;4:e06938
pubmed: 26086719
Cell Rep. 2017 Apr 18;19(3):601-616
pubmed: 28423322
J Theor Biol. 2000 Mar 21;203(2):177-86
pubmed: 10704301
J Pharmacokinet Pharmacodyn. 2009 Apr;36(2):179-97
pubmed: 19387803
Nature. 1976 Dec 9;264(5586):542-5
pubmed: 1004590
BMC Cancer. 2008 Aug 09;8:228
pubmed: 18691423
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Biometrics. 1976 Sep;32(3):535-50
pubmed: 963169
J Thorac Dis. 2013 Aug;5(4):385-92
pubmed: 23991292
Cancer Metastasis Rev. 2010 Dec;29(4):737-50
pubmed: 20878451
Exp Mol Pathol. 2007 Feb;82(1):12-24
pubmed: 16919266
Am J Pathol. 1997 Oct;151(4):1105-13
pubmed: 9327744
Anticancer Res. 2006 Sep-Oct;26(5A):3579-83
pubmed: 17094486

Auteurs

Liang Yang (L)

Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.

Ling Yong (L)

Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.

Xiao Zhu (X)

School of Pharmacy, University of Otago, Dunedin, 9054, New Zealand.

Yaoyao Feng (Y)

Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.

Yu Fu (Y)

Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.

Daming Kong (D)

Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.

Wei Lu (W)

Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.

Tian-Yan Zhou (TY)

Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China. tianyanzhou@vip.sina.com.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH